Opus Genetics
IRDOpus Genetics (NASDAQ: IRD) is a clinical-stage biotechnology company based in the United States. The company's primary business is the development of gene therapies for inherited retinal diseases (IRDs). Its pipeline is built upon foundational research from the University of Pennsylvania and is advanced through a subsidiary model designed to accelerate development. The company’s therapeutic pipeline targets specific genetic forms of blindness. Its lead product candidate, OPGx-LCA5, is in a Phase 1/2 clinical trial for Leber congenital amaurosis (LCA) caused by mutations in the LCA5 gene. Opus Genetics is also developing preclinical programs targeting mutations in the NR2E3 and RHO genes, which are associated with other inherited retinal conditions such as Enhanced S-Cone Syndrome and retinitis pigmentosa. As a publicly traded entity, Opus Genetics operates within the gene therapy sector of the biotech industry. The company’s strategy involves leveraging a platform of adeno-associated virus (AAV) vectors to deliver functional genes directly to retinal cells, with the aim of addressing the underlying genetic cause of these diseases. Its research and development activities are concentrated on advancing its candidates through clinical trials to evaluate their safety and efficacy.
IRD · Stock Price
Historical price data
About
Opus Genetics (NASDAQ: IRD) is a clinical-stage biotechnology company based in the United States. The company's primary business is the development of gene therapies for inherited retinal diseases (IRDs). Its pipeline is built upon foundational research from the University of Pennsylvania and is advanced through a subsidiary model designed to accelerate development. The company’s therapeutic pipeline targets specific genetic forms of blindness. Its lead product candidate, OPGx-LCA5, is in a Phase 1/2 clinical trial for Leber congenital amaurosis (LCA) caused by mutations in the LCA5 gene. Opus Genetics is also developing preclinical programs targeting mutations in the NR2E3 and RHO genes, which are associated with other inherited retinal conditions such as Enhanced S-Cone Syndrome and retinitis pigmentosa. As a publicly traded entity, Opus Genetics operates within the gene therapy sector of the biotech industry. The company’s strategy involves leveraging a platform of adeno-associated virus (AAV) vectors to deliver functional genes directly to retinal cells, with the aim of addressing the underlying genetic cause of these diseases. Its research and development activities are concentrated on advancing its candidates through clinical trials to evaluate their safety and efficacy.